Show simple item record

dc.contributor.authorPratt, G
dc.contributor.authorYap, C
dc.contributor.authorOldreive, C
dc.contributor.authorSlade, D
dc.contributor.authorBishop, R
dc.contributor.authorGriffiths, M
dc.contributor.authorDyer, MJS
dc.contributor.authorFegan, C
dc.contributor.authorOscier, D
dc.contributor.authorPettitt, A
dc.contributor.authorMatutes, E
dc.contributor.authorDevereux, S
dc.contributor.authorAllsup, D
dc.contributor.authorBloor, A
dc.contributor.authorHillmen, P
dc.contributor.authorFollows, G
dc.contributor.authorRule, S
dc.contributor.authorMoss, P
dc.contributor.authorStankovic, T
dc.date.accessioned2018-03-02T14:58:37Z
dc.date.issued2018-08
dc.identifier.citationBritish journal of haematology, 2018, 182 (3), pp. 429 - 433
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1518
dc.identifier.eissn1365-2141
dc.identifier.doi10.1111/bjh.14793
dc.formatPrint-Electronic
dc.format.extent429 - 433
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectLymphoma, Mantle-Cell
dc.subjectLymphoproliferative Disorders
dc.subjectDNA Damage
dc.subjectRecurrence
dc.subjectPiperazines
dc.subjectPhthalazines
dc.subjectSurvival Analysis
dc.subjectMaximum Tolerated Dose
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectTumor Suppressor Protein p53
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell
dc.subjectLeukemia, Prolymphocytic, T-Cell
dc.subjectAtaxia Telangiectasia Mutated Proteins
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.titleA multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bjh.14793
rioxxterms.licenseref.startdate2018-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of haematology
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume182
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Uniten_US
dc.contributor.icrauthorMarsden,en
dc.contributor.icrauthorYap, Christinaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record